---All---
  • ---All---
  • Accession
  • Catalog #

BCL2 Antibody (Center)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AP13823c 0.1 mg 400 ul In Stock $ 255.00 Add to cart
AP13823c-ev20 20 ug 100 ul In Stock $ 95.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

BCL2 Antibody (Center) - Product info

ApplicationWB
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionP10415
Other AccessionP49950, P10417, Q9JJV8, O02718, NP_000624.2
ReactivityHuman, Mouse
PredictedBovine, Hamster, Rat
Concentration0.25 mg/ml
IsotypeRabbit Ig
Calculated MW26266 Da

BCL2 Antibody (Center) - Additional info

Gene ID 596
Other Names
BCL2; Apoptosis regulator Bcl-2
Target/Specificity
This BCL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 85-114 amino acids from the Central region of human BCL2.
Dilution
WB~~1:100~500
Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
BCL2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

BCL2 Antibody (Center) - Protein Information

Name BCL2
Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1)
Cellular Location
Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein Endoplasmic reticulum membrane; Single-pass membrane protein
Tissue Location
Expressed in a variety of tissues.

BCL2 Antibody (Center) - Related products

AP1303a: Bcl-2 Antibody (BH3 Domain Specific)

AP13823c: BCL2 Antibody (Center)

RI10562: BCL2 predesign siRNA

BP1303a: Bcl-2 BH3 Domain Antibody Blocking Peptide

AJ1082a: Bcl-2 Antibody

AF1146a: BCL2 Antibody

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

This gene encodes an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends. [provided by RefSeq].

REFERENCES

Feng, H., et al. Cancer Cell 18(4):353-366(2010) Azad, N., et al. Ann. N. Y. Acad. Sci. 1203, 1-6 (2010) : Dubikov, A.I., et al. Scand. J. Rheumatol. 39(5):368-372(2010) Yu, B., et al. J. Exp. Clin. Cancer Res. 29, 107 (2010) : Trisciuoglio, D., et al. PLoS ONE 5 (7), E11772 (2010) :